Cover Image

Non-Functional Pancreatic Neuroendocrine Tumor: an Enigma

Senthilkumaran R, Amudhan A, Prabhakaran .

Abstract


Pancreatic neuroendocrine tumors (PNET) are rare

and complex neoplasms. They can either present as a

sporadic tumor or as part of various familial syndromes.

Clinical presentation depends on whether the tumor

expresses hormones and also whether the hormones

expressed, can produce symptoms. Diagnosis can be

delayed in non-functional PNET and can have metastatic

disease at the time of presentation. Management depends

on the location and extent of the tumour. This article

presents a case series of non-functional neuroendocrine

tumors managed in our institute.

 


Full Text:

PDF

References


I. M. Modlin, S. F. Moss, B. I. Gustafsson, B. Lawrence, S.

Schimmack, and M. Kidd, “The archaic distinction between

functioning and non-functioning neuroendocrine neoplasms

is no longer clinically relevant,” Langen beck’s Archives of

Surgery, vol. 396, no. 8, pp. 1145–1156, 2011.

J. C. Yao, M. Hassan, A. Phan et al., “One hundred years

after ‘carcinoid’: epidemiology of and prognostic factors for

neuroendocrine tumors in 35,825 cases in the United

States,” Journal of Clinical Oncology, vol. 26, no. 18, pp.

–3072, 2008.

D. C. Metz and R. T. Jensen, “Gastrointestinal

neuroendocrine tumors: pancreatic endocrine tumors,”

Gastroenterology, vol. 135, no. 5, pp. 1469–1492, 2008

K. E. Oberg, “Gastrointestinal neuroendocrine tumors,”

Annals of Oncology, vol. 21, 7, no. 7, pp. vii72-vii80, 2010.

M. H. Kulke, L. B. Anthony, D. L. Bushnell et al.,

“NANETS treatment guidelines: Well-differentiated

neuroendocrine tumors of the stomach and pancreas,”

Pancreas, vol. 39, no. 6, pp. 735–752, 2010.

Zerbi A, Falconi M, Rindi G, DelleFave G, Tomassetti P,

Pasquali C, Capitanio V, Boninsegna L, Di Carlo V.

Clinicopathological features of pancreatic endocrine tumors:

a prospectivemulticenter study in Italy of 297 sporadic

cases. Am J Gastroenterol. 2010;105:1421–1429.

Koukouraki S, Strauss LG, Georgoulias V, et al.

Evaluation of the pharmacokinetics of 68Ga-DOTATOC in

patients with metastatic neuroendocrine tumours scheduled

for 90Y-DOTATOC therapy. Eur J Nucl Med. 2006;33:

–466.

Akerstrom G, Hellman P. Surgery on neuroendocrine

tumours. Best Pract Res ClinEndocrinolMetab 2007; 21:

–109.

Sarmiento JM, Que FG. Hepatic surgery for metastases

from neuroendocrine tumors. SurgOncolClin N Am 2003; 12:

–242.


Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.

An Initiative of The Tamil Nadu Dr MGR Medical University